EGFR and neoplasm: Through the combination of ICO15K-cBiTE AdV, which encodes an EGFR-targeting BiTE, with FR-α-specific CAR T cells, the objective of this study was to address the issue of tumor heterogeneity and the potential loss of tumor antigens.